Point32Health Selects OptumRx for PBM Services
Point32Health is the name of the not-for-profit health care organization formed by the merger of Harvard Pilgrim Health Care and Tufts Health Plan.
Point32Health, the not-for-profit health care parent company of Harvard Pilgrim Health Care and Tufts Health Plan, has entered into a new, multi-year agreement with OptumRx to provide integrated PBM solutions beginning January 1, 2023,
OptumRx officials said the new agreement is expected to generate aggregate pharmacy savings for commercial, direct and medicare customers of between 12% and 16% over the course of the three-year contract.
OptumRx has served Harvard Pilgrim members since January 1, 2020, and will work closely with Tufts Health Plan's current pharmacy benefit partner, CVS Caremark, to ensure a smooth transition.
Cain Hayes
“We look forward to collaborating with [OptumRx] to ensure our members have the most competitive prescription drug benefits program available and that our Tufts Health Plan members experience a smooth transition to OptumRx,” Cain Hayes, CEO of Point32Health, said in a statement.
Point32Health’s pharmacy services department will continue to manage its prescription drug program, including decisions about which drugs are included in its formularies and the specialty pharmacy program offering.
Point32Health provides health care to 2.3 million members across New England. Harvard Pilgrim Health Care and Tufts Health Plan combined their organizations January 1, 2021. At the time, company officials indicated they could save more than $100 million through administrative synergies, which they said would be used to mitigate premium increases and member out-of-pocket burden.
The Point32Health name is inspired by the 32 points on a compass
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Advisory Committee Votes Down Sotagliflozin in Type 1 Diabetes and CKD
November 1st 2024Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
Read More
ICER Gives Cell Therapy for Post-Transplant Complications High Rating
Published: October 31st 2024 | Updated: October 31st 2024ICER has given tabelecleucel a rating of A, indicating the T cell therapy for Epstein-Barr virus related post-transplant lymphoproliferative disease has a high certainty of substantial net health benefit and would be cost-effective if priced between $143,900 and $273,700.
Read More
